Director of HIV Research Strategy
Associate Specialist in HIV Medicine
Chelsea and Westminster Hospital
London, United Kingdom
- New drug development
- Co-receptor antagonism
- Metabolic and morphological toxicities
- Emerging toxicities
- Initial therapy
- Prevention and management of antiretroviral toxicity
Dr Graeme Moyle is Director of HIV Research Strategy and Associate Specialist in HIV Medicine at the Chelsea and Westminster Hospital in London, United Kingdom. Dr Moyle received his medical degree (MBBS) and doctorate (MD) from the University of Adelaide in Adelaide, South Australia. Dr Moyle coordinates phase 2 through 4 research at the Chelsea and Westminster Hospital and manages a large cohort of persons with HIV infection. His research interests include the clinical development of new antiretrovirals, pharmacokinetics, and metabolic and morphologic complications of HIV disease. He has published extensively on these subjects in journals including The Lancet, AIDS, JAIDS, Journal of Infectious Diseases, and Nature Medicine.
Dr Moyle serves on the British HIV Association Treatment Guidelines Writing Committee and is a medical advisor for the UK National AIDS Manual. In addition, he is Editor of The Journal of Viral Entry, the past editor (2000-2006) of the HIV section of Current Opinion in Infectious Diseases and on the Editorial Boards of Drug Safety, AIDS Reviews, HIVandhepatitis.com, and Medscape. He is an expert advisor for TheBody.com and Medscape, as well as a regular columnist for The AIDS Reader.
- British HIV Association Treatment Guidelines (1996-present)
- Riverside Research Ethics Committee (2002-present)
- UK National AIDS Manual (1996-present)
- University of Adelaide, Faculty of Medicine (1980-1985)
- University of Adelaide, MBBS (1986)
- Society of Apothecaries, London, Graduate Diploma of Genito-Urinary Medicine, (1989)
- University of Adelaide, MD (1996)
- Boffito M, Winston A, Jackson A, Fletcher C, Pozniak A, Nelson M, Moyle G, Tolowinska I, Hoetelmans R, Miralles D, Gazzard B. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS. 2007;21:1449-1455.
- Moyle GJ, Lysakova L, Brown S, Sibtain N, Healy J, Priest C, Mandalia S, Barton SE. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20(16):2043-2050
- Moyle G, Higgs C, Teague A, Mandalia S, Nelson M, Johnson M, Fisher M, Gazzard B. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Antiviral Therapy 2006;11:73-78.
- Maitland D, Moyle G, Hand J, Mandalia S, Boffito M, Nelson M, Gazzard B. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 2005;19:1183-1188.
- Moyle GJ, DeJesus E, Cahn P, Castillo SA, Zhao H, Gordon DN, Craig C, Scott TR; Ziagen Once-Daily in Antiretroviral Combination Therapy (CNA30021) Study Team. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr. 2005;38:417-425
- Jones SP, Qazi N, Morelese J, Lebrecht D, Sutinen J, Yki-Jarvinen H, Back DJ, Pirmohamed M, Gazzard BG, Walker UA, Moyle GJ.
Assessment of Adipokine Expression and Mitochondrial Toxicity in HIV Patients With Lipoatrophy on Stavudine- and Zidovudine-Containing Regimens. Journal of Acquired Immune Deficiency Syndromes 2005;40:565-572
- Moyle GJ, Lysakova L, Brown S, Sibtain N, Healy J, Priest C, Mandalia S, Barton SE. A randomised open label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Medicine 2004;5:82-87.
- Moyle GJ, Daar ES, Gertner JM, Kotler DP, Melchior JC, O'brien F, Svanberg E; Serono 9037 Study Team. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome 2004;35: 367-375
- Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, Gazzard BG. Epidemiology and Predictive Factors for Chemokine Receptor Use in HIV-1 Infection. J Infect Dis. 2005;191:866-872.